Macrogenics (MGNX) Misses Q1 EPS by 29c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Macrogenics (MGNX) Misses Q1 EPS by 29c, Revenues Miss

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

April 29, 2021 4:01 PM EDT

MARGENZA launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCOConference call scheduled for today at 4:30 p.m. ET.

ROCKVILLE, Md., April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2021.

With the recent launch and commercialization of MARGENZA, we are delivering on... More